Choose Your News
Loading...
Tags:
Morphosys AG (MOR) announces the successful outcome of a Phase 2 clinical trial, L-MIND, evaluating lead candidate MOR208, combined with Celgene's (CELG) R... [Read More]
The European Commission has approved two of Celgene's IMiD®-based combination regimens:... [Read More]
The Bristol-Myers deal with Celgene includes a $9 CVR component. Three drugs must get FDA approvals by deadlines for the CVR to pay out. We... [Read More]
May 15, 2019... [Read More]
Thumbnail
Die Celgene Corporation (NASDAQ: CELG) hat die Ergebnisse einer Post-Hoc-Analyse der Daten aus der Phase-III-Studie RADIANCE™ Teil B veröffentlicht. D... [Read More]
Celgene plans to submit sNDA by end of 2019... [Read More]
The FDA designates Celgene's (CELG) POMALYST (pomalidomide) a Breakthrough Therapy for the treatment of patients with human immunodeficiency virus ((HIV)) [Read More]
May 13, 2019--Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to POMALYST® (pomalidomide) for the... [Read More]
Preview